Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Metastatic disease~* Documented disease progression~  * Must have received and subsequently failed (due to disease progression) ≥ 2 prior sequential endocrine therapies for treatment of metastatic breast cancer~    * Disease progression during adjuvant tamoxifen is considered 1 prior therapy~   * The 2 most recent treatments must have been endocrine agents~* At least 1 objective measurable disease parameter~* Brain metastases allowed provided both of the following criteria are met:~  * Brain metastases were previously treated AND are currently stable~ * Brain metastases are not the only site of metastatic disease~* Hormone receptor status~  * Estrogen and/or progesterone receptor-positive tumor~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Postmenopausal, as defined by any of the following:~  * At least 50 years of age with an intact uterus AND amenorrheic for the past 12 months~ * At least 50 years of age without a uterus AND follicle-stimulating hormone (FSH) level within postmenopausal range~ * Under 50 years of age and FSH level within postmenopausal range~ * Prior bilateral oophorectomy~Performance status~* ECOG 0-2~Life expectancy~* At least 6 months~Hematopoietic~* Adequate hematologic function~Hepatic~* Adequate hepatic function~* Bilirubin ≤ 1.5 times upper limit of normal~* No history of hepatic adenoma~Renal~* Adequate renal function~* No history of hypercalcemia or severe hypocalcemia~Cardiovascular~* No history of thrombophlebitis or thromboembolic disorders associated with prior estrogen use~* No active thrombophlebitis or thromboembolic disorders~* No history of uncontrolled hypertension~Other~* Not pregnant~* No undiagnosed abnormal vaginal bleeding~* No other serious medical illness~* No psychiatric illness that would preclude giving informed consent~* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Prior chemotherapy for metastatic disease allowed~* Prior adjuvant chemotherapy allowed~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* Prior radiotherapy allowed provided the only site of measurable disease was not irradiated~Surgery~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).